Welcome
Support Centre
20 September 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
STHLM3 - Prostate cancer diagnostic trial
ISRCTN ISRCTN84445406
DOI 10.1186/ISRCTN84445406
ClinicalTrials.gov identifier
EudraCT number
Public title STHLM3 - Prostate cancer diagnostic trial
Scientific title STHLM3 - Prostate cancer diagnostic randomized trial
Acronym STHLM3
Serial number at source N/A
Study hypothesis STHLM3 [STHLM relates to the city of Stockholm, Number 3 relates to that this is the third study within the same setting] is a randomized controlled trial aiming to assess whether a panel of biomarkers for prostate cancer can substantially reduce the proportion of men referred to biopsy whilst maintaining sensitivity for high risk prostate cancer.
Lay summary Lay summary under review 2
Ethics approval Stockholm Ethical Review Board, 09 May 2012, ref: r DNR 2012/572-31/1
Study design Two-armed randomized controlled trial
Countries of recruitment Sweden
Disease/condition/study domain Prostate cancer
Participants - inclusion criteria All men between 50 and 69 years of age who have a permanent postal address in Stockholm County Council or Region Gotland (N=260,000) will be asked whether they would like to take part in STHLM3.
Participants - exclusion criteria Diagnosed with prostate cancer
Anticipated start date 01/01/2013
Anticipated end date 31/12/2014
Status of trial Ongoing
Patient information material Patient information in Swedish can be found at http://sthlm3.se/dokument/
Target number of participants 140,000
Interventions The two study arms will be:

Control/PSA arm, where referral to biopsy will be based on Prostate-specific antigen (PSA) only with PSA ≥ 3 as the level of referral to prostate biopsy

Intervention/Best biomarker panel (BBP) arm, where referral to biopsy will be determined by a risk prediction model based on age, an array of single-nucleotide polymorphism (SNPs), family history and protein-based biomarkers.
Primary outcome measure(s) To increase the specificity of a combined prostate cancer test compared to the PSA test without decreasing the sensitivity of high risk of prostate cancers (defined as Gleason 7 or higher). The primary endpoint is number of prostate biopsies.
Secondary outcome measure(s) 1. To decrease the number of low risk prostate cancers diagnosed
2. To increase the health related quality of life and knowledge of prostate cancer testing
3. To assess the health economic consequences of implementing prostate cancer screening
4. To improve the quality and effectiveness of prostate cancer diagnosis in the routine health care in Stockholm
5. To assess the overall long-term mortality of prostate cancer in the Stockholm/Gotland area over a 10-15 year period
6. To assess the combination of a blood based “best biomarker panel” and urine biomarkers in men with initial negative prostate biopsy (separate study protocol STHLM3-Rebiopsy) and
7. To facilitate inclusion in active surveillance protocol in men diagnosed with low risk prostate cancers
Sources of funding Stockholm County Council (Sweden)
Trial website http://sthlm3.se
Publications
Contact name Prof  Henrik  Grönberg
  Address Nobels väg 12
  City/town Stockholm
  Zip/Postcode 17177
  Country Sweden
Sponsor Karolinska Institutet (Sweden)
  Address Department of Medical Epidemiology and Biostatistics
PO Box 281
  City/town Stockholm
  Zip/Postcode 17177
  Country Sweden
  Sponsor website: http://ki.se/ki/jsp/polopoly.jsp?l=en&d=9600
Date applied 14/11/2012
Last edited 03/01/2013
Date ISRCTN assigned 03/01/2013
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.